血管病是西方國家最常見的死因，其發(fā)病率在發(fā)展中國家呈上升趨勢。因此，大量的研究旨在建立有效的治療急性血管事件。長期治療也受到了相當大的關(guān)注（例如癥狀緩解）。此外，有效的預防，無論是一級還是二級，都得到了幾個具有里程碑意義的試驗結(jié)果的支持。血管疾病是一個復雜的領(lǐng)域，有初級保健醫(yī)師和護士從業(yè)人員以及涉及的幾個專業(yè)。后者包括心臟病學、血管和心胸外科、普通醫(yī)學、放射學、臨床藥理學和神經(jīng)學（中風單元）。目前的血管藥理學將發(fā)表評論，以更新所有與血管疾病治療有關(guān)的。例如，對最近發(fā)表的試驗或新藥的評論將包括在內(nèi)。除了臨床相關(guān)主題外，我們還將考慮“基于研究”的評論，以處理未來的發(fā)展和潛在的藥物目標。因此，當前血管藥理學的另一個功能是彌合臨床實踐和正在進行的研究之間的差距。本雜志的通訊部分也將鼓勵辯論。

Vascular disease is the commonest cause of death in Westernized countries and its incidence is on the increase in developing countries. It follows that considerable research is directed at establishing effective treatment for acute vascular events. Long-term treatment has also received considerable attention (e.g. for symptomatic relief). Furthermore, effective prevention, whether primary or secondary, is backed by the findings of several landmark trials. Vascular disease is a complex field with primary care physicians and nurse practitioners as well as several specialties involved. The latter include cardiology, vascular and cardio thoracic surgery, general medicine, radiology, clinical pharmacology and neurology (stroke units). Current Vascular Pharmacology will publish reviews to update all those concerned with the treatment of vascular disease. For example, reviews commenting on recently published trials or new drugs will be included. In addition to clinically relevant topics we will consider 'research-based' reviews dealing with future developments and potential drug targets. Therefore, another function of Current Vascular Pharmacology is to bridge the gap between clinical practice and ongoing research. Debates will also be encouraged in the correspondence section of this journal.